title: Evaluation of the Oral Bioavailability of Low Molecular Weight Heparin Formulated With Glycyrrhetinic Acid as Permeation Enhancer.
abstract: Low molecular weight heparin (LMWH) is the agent of choice for anticoagulant therapy and prophylaxis of thrombosis and coronary syndromes. However, its therapeutic use is limited due to poor oral bioavailability. The aim of this study was to investigate the oral delivery of LMWH, ardeparin formulated with 18-beta glycyrrhetinic acid (GA), as an alternative to currently used subcutaneous (sc) delivery. Drug transport through Caco-2 cell monolayers was monitored in the presence and absence of GA by scintillation counting and transepithelial electrical resistance. Regional permeability studies using rat intestine were performed using a modified Ussing chamber. Cell viability in the presence of various concentrations of enhancer was determined by MTT assay. The absorption of ardeparin after oral administration in rats was measured by an anti-factor Xa assay. Furthermore, the eventual mucosal epithelial damage was histologically evaluated. Higher ardeparin permeability (~7-fold) compared to control was observed in the presence of 0.02 % GA. Regional permeability studies indicated predominant absorption in the duodenal segment. Cell viability studies showed no significant cytotoxicity below 0.01 % GA. Ardeparin oral bioavailability was significantly increased (F(relative)/(S.C). = 13.3%) without causing any damage to the intestinal tissues. GA enhanced the oral absorption of ardeparin both in vitro and in vivo. The oral formulation of ardeparin with GA could be absorbed in the intestine. These results suggest that GA may be used as an absorption enhancer for the oral delivery of LMWH.
authors: Nusrat A
authors: NA
authors: Motlekar
authors: Kalkunte S
authors: KS
authors: Srivenugopal
authors: Mitchell S
authors: MS
authors: Wachtel
authors: Bi-Botti C
authors: BB
authors: Youan
references: N Engl J Med. 2001 Mar 1;344(9):626-31
references: 11228276
references: Am J Hematol. 2001 May;67(1):10-4
references: 11279651
references: Cardiovasc Surg. 2001 Jun;9(3):211-8
references: 11336843
references: Biol Pharm Bull. 1994 Oct;17(10):1399-403
references: 7874064
references: J Vasc Surg. 1999 Sep;30(3):526-31
references: 10477646
references: Pharm Res. 1994 Aug;11(8):1132-42
references: 7971714
references: Chem Pharm Bull (Tokyo). 1982 Jun;30(6):2245-7
references: 7127610
references: J Drug Target. 1998;5(3):215-23
references: 9606011
references: Drug Dev Ind Pharm. 2002 Sep;28(8):1033-41
references: 12378958
references: Am J Physiol. 1991 Aug;261(2 Pt 1):G312-9
references: 1872400
references: J Pharm Pharmacol. 1996 Dec;48(12):1285-9
references: 9004192
references: J Pharm Sci. 1969 Nov;58(11):1372-5
references: 5349752
references: Endocrinol Jpn. 1967 Mar;14(1):39-42
references: 6072412
references: Biol Pharm Bull. 1995 Apr;18(4):566-70
references: 7655429
references: J Pharm Pharmacol. 1999 Nov;51(11):1241-50
references: 10632081
references: J Pharm Sci. 1997 Oct;86(10 ):1105-10
references: 9344165
references: Thromb Res. 1989 Oct 1;56(1):119-24
references: 2595670
references: Pharm Res. 1999 Jan;16(1):80-6
references: 9950283
references: Chem Pharm Bull (Tokyo). 1992 Jun;40(6):1559-62
references: 1394677
references: Am J Physiol. 1999 Sep;277(3 Pt 1):C554-62
references: 10484342
references: Am J Physiol. 1987 Jan;252(1 Pt 2):F188-97
references: 3101512
references: Pharm Res. 1988 Jun;5(6):341-6
references: 3244645
references: J Pharmacobiodyn. 1989 Jan;12(1):31-6
references: 2656985
references: J Pharm Sci. 2000 Apr;89(4):429-42
references: 10737905
references: J Cell Physiol. 1995 Sep;164(3):533-45
references: 7650061
references: Thromb Res. 1976 Mar;8(3):413-6
references: 1265712
references: Haemostasis. 1995 Nov-Dec;25(6):288-98
references: 8586320
references: Baillieres Clin Haematol. 1990 Jul;3(3):651-84
references: 2148697
references: Pharm Res. 2001 Nov;18(11):1638-41
references: 11758776
references: J Pharm Sci. 1995 Jun;84(6):682-7
references: 7562404
references: Biomacromolecules. 2005 Jan-Feb;6(1):168-73
references: 15638517
references: AAPS J. 2004 Oct 21;6(4):e31
references: 15760096
references: Wien Med Wochenschr. 2003;153(19-20):426-33
references: 14648923
references: Biochem J. 1988 Dec 15;256(3):1039-41
references: 3146979
references: J Pharm Sci. 2004 Dec;93(12):2985-93
references: 15468328
references: Curr Drug Deliv. 2005 Jul;2(3):277-87
references: 16305430